

I.b

Nexxt MedTech Inc.

Executive Summary

The vision of Nexxt MedTech is to address chronic pain through a scientifically backed safe and effective user-friendly smart device that delivers relief via electrical stimulation. Our value proposition is to further develop and perfect this device based on **Intelligent Quantum BioPhysics Electrostimulation**.

Market Analysis

According to the CDC, 20.9% of US adults, or 51.6 million people, experienced chronic pain in 2021. Chronic pain is defined as pain that occurs on most or every day over a three-month period.

The CDC also states that 6.9% (17.1 million) of Americans suffer **high impact** pain. High impact pain is pain that results in a substantial restriction to daily activities.

While there are many agencies that have done clinical studies on pain and the one commonality is that they all agree that the numbers of those suffering pain is the largest medical problem faced by Americans.

While this is most concerning to the individual there is an estimated cost of **\$560 billion to \$635 billion dollars** annually in the U.S in lost productivity, medical expenses and addiction.

Technology and Product Description

Nexxt MedTech is a company formed in Colorado to undertake the commercial development of a refined home use device to treat chronic pain.

The inventor Claudio Tassi developed the current device and together with testing by Steve Jacobs and a few doctors the device has proven its ability to resolve chronic pain.

The science of **Intelligent Quantum BioPhysics Energy** is an interdisciplinary field that explores the intersections of quantum mechanics, electromagnetism, biology, and physics.

It focuses on how quantum phenomena influence biological processes and systems. We use electromagnetism as the basis for our technology and how it influences pain relief.



Nexxt Medtech Inc
427 Wright Street #205,
Lakewood, Colorado 80228

The fundamental point is to operate on the cause and not only on the effects of pain; this is possible only by interacting with the biochemical systems and activating a mechanism for storing corrective signals.

Once commercial operations are established we will add an AI component which will analyze data harvested from previous treatment sessions. This will allow further optimization for each patient.

Further Intelligent Quantum BioPhysics Electrostimulation is the technique that use electrical stimulation based on principles derived from biophysics and quantum concepts to influence cellular processes, improve healing, and optimize biological functions.

It is a method to optimize energy flow in the body, enhance cell regeneration, reduce pain, and balance the body's bioenergetics field.

The operational heart of the system, based on more than 30 years of research and tests, has the real-time ability to adapt the frequency of microstimulations to the real needs of the patient's body undergoing therapy.

The absolute specificity of the stimulation sequences guarantees an immediate therapeutic patient response.

Claudio developed the understanding of how to use electrical stimulation and also understands the effects of this stimulation on human biology.

The device sends stimulus then reads the impact of the therapy through its biofeedback ability immediately adjusting the therapy accordingly.

The challenge is to take the relatively complex existing smart device which contains a touch screen with microprocessor and a current generator and reduce the size and complexity so that the device is less costly to manufacture and much easier for the patient to use at home.

To this end we are working with Vantage MedTech, a deeply experienced company designing, manufacturing and obtaining FDA certification of medical devices.

We have a working plan ready to implement.



Team Overview

The Scientific Staff IS one of the greatest resources of this project, which includes thirty years of experience in the field of biomolecular research, systemic and functional medicine, biomechanics, genetics, quantum physics, medical bioengineering and robotics.

Collaborations around the world with the most renowned research centers and with health care organizations have now lasted ten years.

- Dr. Claudio Franco Tassi Chief science officer and Inventor – Molecular Biologist, Orthomolecular Medicine, Electroneuronal Medical Therapy and Quantitstic NIs applied to biological systems, degree.
- Steven Jacobs is an experienced entrepreneur with startup experience in multiple industries.
- His experience includes the creation and sale of a business to a German public company where he also managed multiple countries for 4 years. Steve understands the early needs of a startup and is very hands-on while he builds out the team to grow the business.
- Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization.
- They have developed medical devices such as intraoral cameras, cardiac pump controllers and radiofrequency ablation for nerve tissue to name a few. Vantage MedTech is a trusted partner of the FDA and is trusted to test devices developed and engineered by them.
- They are allowed to test according to FDA requirements and submit results for certification.
- They are also trusted my many countries including CE in the EU. This brings into the project an efficient partner to manage the regulatory requirements of our product.

NMT
NEXXT MEDTECH

 Next Medtech Inc
427 Wright Street #205,
Lakewood, Colorado 80228

The Pain Industry

Chronic pain is a debilitating condition that affects the lives of millions of adults in the United States. There are a multitude of methods for treating pain.

Medications:

- Analgesics: Over-the-counter options like acetaminophen or NSAIDs.
- Prescription medications: Opioids, certain antidepressants, or anticonvulsants may be used.
- Topical treatments: Creams or patches that contain pain-relieving ingredients.

Physical Therapy:

- Tailored exercises and stretches to improve mobility and strength.
- Techniques like ultrasound or electrical stimulation. This refers to Tens or IFC which deliver stimulus only as directed by the technician.

Interventional Procedures:

- Injections (e.g., corticosteroids) to reduce inflammation.
- Nerve blocks or other minimally invasive procedures.
- Surgery to fuse vertebrae and other more extreme surgical interventions.

Marketing Strategy

The first group we will target is the older generation. This comprises those over 65. Many in this age group suffer with chronic pain and they are a significant portion of people with high impact pain.

They are also the best group to target initially because are readily marketed to through the following methods:

- Facebook ads
- Direct mail
- Seminars at aged persons facilities
- Targeting of loved ones who wish to help



We will also develop customer education materials as chronic pain patients may not be familiar with Intelligent Quantum BioPhysics Electrostimulation. We will develop educational content (videos, guides, and FAQs) to help patients understand how it works and gain confidence in the technology.

After the first target group we will have broader patient targeting such as younger patients who suffer from chronic conditions. They are often more tech-savvy and interested in non-pharmaceutical pain management solutions, and they might be less reluctant to adopt new technology.

The second group will be targeted via professional recommendations. We will partner with physical therapist clinics (38,000 private clinics in US), chiropractor's (65,000 practicing in the US) and massage therapists (320,000 practicing in the US).

Marketing Plan

Persistent Pain is the most medical problem people suffer from today. When we see that up to 20.9% (51.6 million) of the general population suffers pain with 6.9% (17.1 million) suffering high impact pain (defined by the CDC as pain that affects work or life). If we treat only 1% of the 17.1 million people, we already have a very large market. Our lowest revenue per user is \$400 per year (to receive this low cost they also need to buy our device) and if this was all our revenue we would have \$68.4 million annually. This is our 5-year target although revenues will be higher due to rentals and sales of the device. Revenues will be larger as not everyone will buy the device, and rentals have higher annual cost.

This document lays out the early through to later marketing and sales strategy. Early marketing will be focused on the Denver metro area where we are located. The focus will be on 65-year-old plus people. This is due to several factors. Older people suffer more pain chronically than others, they have more time to treat their pain and it affects their quality of life more (as a percentage of their population) and they have more time to treat their pain. Our activities for launch are:

- Outreach through Facebook advertising and US Postal direct mail service will bring us clients interested in treating their chronic pain.
- We will also have a center in our office to allow people to come in to trial the device and receive instruction on use. This will improve confidence by allowing them to try the device first prior to committing.

NMT
NEXXT MEDTECH

 Next Medtech Inc
427 Wright Street #205,
Lakewood, Colorado 80228

- Seminars in retirement homes to introduce and demonstrate the device.
- Phone sales and support center to help with any user issues and follow up on leads generated in Facebook.

Once initial traction is obtained, we will define the next geographic areas to enter, and we will use the above marketing methods combined with broad market communications such as:

- Google pay per click to drive people to our website.
- Radio for expanding knowledge of our product and its results.
- Television.

Partnership with Chiropractors, Regenerative medicine clinics, physical therapy clinics, etc. will offer marketing to their patients. This is approached at a later stage due to the loss of margin it requires.

Implementation and Timeline

The first year will be required for the design, engineering, FDA certification, building and testing of the first units.

In the second year, production, marketing and sales will begin. During this second year we will be building our knowledge of and honing our marketing methods.

Sales will begin slowly and build through the end of the year. We will also build and train a phone support center which will follow up sales leads and provide how to use support for people having difficulty setting up the device.

In the third year, sales will grow at a quicker pace, and we will be making decisions on how to increase the sales at much faster rates in the following years.

Financial Projections

The first year will be design, engineering, testing and certification. The expense for this is \$2,039,000.

The second year will see the start of sales with projected delivery of 4,000 units resulting in sales of \$5.7 million with expenses and costs of sales of \$2.7 million leaving us at break even by the end of the second year.



Revenue is comprised of rental at \$300 per month for the first six months. If they wish to purchase the price is \$6,000 with a \$900 credit for half the initial rental period. They will then pay \$5,100 for the device and \$400 for the first year's access to the platform. We expect that 10% will purchase and the balance will continue to rent at a lower post six-month rate of \$200 per month.

The third year we project to deliver 9,500 units for \$32,000,000 in sales with COGs of \$7.7 million and expenses of \$5.4 million. Leaving us with a net before tax of over \$16 million.

During the third year we will be prepared to spend more on marketing in order to achieve even higher sales and further prepare to hit sales in excess of \$70 million by the end of year five.



Year One	1st Qtr	2nd Qtr	3rd Qtr	4th Qtr
Revenue	-	-	-	-
COGS	-	-	-	-
Design/engineering	458,333	441,667	367,500	340,000
Marketing	-	13,333	12,667	19,000
Operating Expense	41,250	41,250	90,000	154,000
General & Administration	-	-	-	60,000
Profit	-499,583	-496,250	-470,167	-573,000

Year Two	1st Qtr	2nd Qtr	3rd Qtr	4th Qtr
Revenue	-	525,000	1,768,605	3,380,774
COGS	-	800,000	1,174,429	1,370,622
Design/engineering	152,500	-	-	-
Marketing	39,000	134,000	209,103	224,746
Operating Expense	162,000	241,000	383,891	572,826
General & Administration	60,000	60,000	61,200	61,800
Profit	-413,500	-710,000	-60,018	1,150,780

NMT
NEXXT MEDTECH

Next Medtech Inc
427 Wright Street #205,
Lakewood, Colorado 80228

Year Three	1st Qtr	2nd Qtr	3rd Qtr	4th Qtr
Revenue	5,040,815	6,861,451	8,915,897	11,240,566
COGS	1,566,311	1,776,623	2,013,576	2,281,472
Design/engineering	-	-	-	-
Marketing	249,849	279,603	313,584	352,397
Operating Expense	759,492	926,279	1,066,895	1,238,688
General & Administration	61,800	61,800	61,800	61,800
Profit	2,403,364	3,817,147	5,460,042	7,306,208



Investment Opportunity

We are offering 200,000 shares for \$18 each. Nexxt MedTech is a C corporation formed in Colorado.

Near to the end of the third year we would apply for a Reg. A listing which would allow any that desire to exit from that point forward.

It is the founder's intention to grow this business with a view to rapid growth. We believe this technology has a tremendous growth possibility with sales potentially in the hundreds of millions of dollars or even a billion dollars!

Claudio and Steve have 250,000 shares.

Claudio has invested more than 30 years developing this technology and the development of various clinical devices. Steve has spent 6 years working with Claudio to investigate and trial markets to determine the most suitable path forward. More than \$2,000,000 has been spent to design and build current devices, software and treatment protocols.

Exit possibilities: While it is very early to predict how an investor might exit this investment, we believe in the third year we will have achieved sufficient results to register a series A which would allow shares to be sold freely.

Profits of the magnitude of \$17m are large enough to attract high growth multiples in valuation.

I estimate that sales and profit growth in the 4th and 5th years would establish the business as high growth with continued high growth potential for many years to come. It would be possible to speculate on many other possibilities, but I feel the time for this would be in the third year. Investors should know that Claudio and Steve are committed to the long term of this business and would consider any rational plan presented.

